Plerixafor (AMD3100), a small molecule bicyclam CXCR4 antagonist, is FDA approved for autologous stem cell mobilization in non-Hodgkin’s lymphoma and multiple myeloma (MM)134,135. The gene discussed is CXCR4; the disease is Miyoshi myopathy.